Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy Company
February 28, 2019 6:51 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $192.00 (from $199.00) while maintaining a Outperform rating.
"We believe this quarter is marking the emergence of SRPT as a full-fledged gene therapy company and leader in neuro GT drug... More
Sarepta Therapeutics (SRPT) PT Raised to $213 at Cowen
February 28, 2019 6:21 AM ESTCowen analyst Ritu Baral raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $213.00 (from $178.00) while maintaining a Outperform rating.
Baral commented, "SRPT reported 4Q18 with pre-announced Exondys revenues only slightly below consensus but meeting FY18 guidance. SRPT provided timeline updates for its... More
Sarepta Therapeutics (SRPT) Tops Q4 EPS by 19c, Revenues Miss
February 27, 2019 4:15 PM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.85), $0.19 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $84.42 million versus the consensus estimate of $86.02 million.
2018 was a year of transformation for Sarepta. We continued to execute commercially, announced unprecedented early results... More
